| Literature DB >> 34885168 |
Yuan-Yuan Lei1, Suzanne C Ho2, Ka-Li Cheung1, Victoria A Yeo1, Roselle Lee1, Carol Kwok3, Ashley Cheng3, Frankie K F Mo1,4, Winnie Yeo1,4.
Abstract
Evidence about the association between the level of sports activities participation post-diagnosis and quality of life (QoL) among Chinese women with early-stage breast cancer is limited. A validated modified Chinese Baecke questionnaire was used to prospectively measure sports activities among a breast cancer cohort at four time-points: baseline and 18, 36, and 60 months after diagnosis (sports activities during the previous 12 months before each interview); QoL was measured at the same time. In total, 1289, 1125, and 1116 patients were included in the analyses at 18-, 36- and 60-month follow-up, respectively. The percentages of patients who belonged to no (0 metabolic equivalent of task (MET)-hours per week), low-level (<10 MET-hours/week), and high-level (≥10 MET-hours/week) sports activities group were 20.7%, 45.5%, and 33.8% at 18-month follow-up, respectively; the corresponding figures at 36 and 60 months differed slightly. Using data from the three follow-ups, generalized estimating equation (GEE) analyses showed that higher levels of sports activities participation were associated with better QoL in several items as well as fewer symptoms. The present findings in Chinese women with breast cancer provide important evidence on the beneficial effect of regular participation in sports activities following cancer diagnosis on patients' QoL.Entities:
Keywords: Chinese women; breast cancer; quality of life; sports activity; the first five years of survival
Year: 2021 PMID: 34885168 PMCID: PMC8656618 DOI: 10.3390/cancers13236056
Source DB: PubMed Journal: Cancers (Basel) ISSN: 2072-6694 Impact factor: 6.639
Demographic, clinical, and lifestyle characteristics of patients by level of sports activities at 18-, 36- and 60-month follow-up.
| Characteristics | Level of Sports Activities at 18-Month FU, | Level of Sports Activities at 36-Month FU, | Level of Sports Activities at 60-Month FU, | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ( | ( | ( | ||||||||||
| No | Low-Level Group | High-Level Group |
| No | Low-Level Group | High-Level Group |
| No | Low-Level Group | High-Level Group |
| |
| ( | ( | ( | ( | ( | ( | ( | ( | ( | ||||
| Level of sports activity, MET-hour/week, mean ± SD | 0 | 4.2 ± 2.8 | 23.4 ± 14.0 | 0 | 4.3 ± 2.8 | 25.8 ± 16.1 | 0 | 4.6 ± 2.8 | 25.3 ± 17.2 | |||
| Age at FU, mean ± SD, year | 53.5 ± 9.3 | 53.3 ± 9.1 | 54.3 ± 8.6 | 0.24 | 54.9 ± 8.9 | 54.7 ± 9.1 | 56.4 ± 8.1 | 0.019 | 56.4 ± 8.8 | 56.7 ± 9.2 | 58.3 ± 8.5 | 0.202 |
| Education level, % | 0.003 | 0.026 | 0.004 | |||||||||
| High school or below | 91 | 82.1 | 84.6 | 89.4 | 82.9 | 83.4 | 89.3 | 81 | 82.6 | |||
| College or above | 9 | 17.9 | 15.4 | 10.6 | 17.1 | 16.6 | 10.7 | 19 | 17.4 | |||
| Marital status, % | 0.081 | 0.106 | 0.563 | |||||||||
| Married or cohabitating | 70.8 | 68.1 | 74.5 | 68.9 | 70.8 | 75.8 | 69.9 | 73.4 | 71.8 | |||
| Unmarried or divorced or widowed | 29.2 | 31.9 | 25.5 | 31.1 | 29.2 | 24.2 | 30.1 | 26.6 | 28.2 | |||
| Household income, HKD/month | 0.054 | 0.009 | 0.109 | |||||||||
| <15,000 | 54.3 | 44.7 | 44.3 | 51.7 | 43.8 | 43.5 | 50 | 43.9 | 43.2 | |||
| 15,000–29,999 | 28.5 | 31.2 | 32.1 | 31.1 | 33.3 | 28.4 | 31.7 | 30.7 | 31.5 | |||
| ≥30,000 | 17.2 | 24.1 | 23.6 | 17.2 | 22.8 | 28.1 | 18.3 | 25.4 | 25.3 | |||
| Employment status | 0.086 | 0.133 | 0.225 | |||||||||
| Full time | 34.1 | 35.7 | 40.8 | 34.4 | 36.1 | 42.4 | 36.1 | 33.9 | 42.1 | |||
| Part time | 16.1 | 12.1 | 14.7 | 14.5 | 11.4 | 12.4 | 12.8 | 13.7 | 11.2 | |||
| Not working | 49.8 | 52.2 | 44.5 | 51.1 | 52.5 | 45.2 | 51.1 | 52.4 | 46.8 | |||
| No. of comorbidities, % | 0.273 | 0.528 | 0.623 | |||||||||
| 0 | 55.4 | 61.9 | 62.6 | 59.2 | 62.8 | 61.5 | 60.7 | 62.7 | 61.5 | |||
| 1 | 28.5 | 25.3 | 25.9 | 25.7 | 24 | 27.2 | 24.6 | 26.3 | 25 | |||
| ≥2 | 16.1 | 12.8 | 11.5 | 15.1 | 13.2 | 11.2 | 14.8 | 11 | 13.5 | |||
| Menopausal status at FU, % | 0.027 | 0.039 | 0.256 | |||||||||
| Pre-menopausal | 25.1 | 22.5 | 17.2 | 24.5 | 22.4 | 16.9 | 17.5 | 18 | 13.8 | |||
| Post-menopausal | 74.9 | 77.5 | 82.8 | 75.5 | 77.6 | 83.1 | 82.5 | 82 | 86.2 | |||
| AJCC stage, % | 0.518 | 0.472 | 0.051 | |||||||||
| 0-I | 36.3 | 35 | 36.9 | 35 | 38.6 | 35.1 | 38.8 | 37.3 | 38.2 | |||
| II | 43.1 | 45.7 | 46.8 | 46.5 | 46.1 | 48.9 | 41.5 | 48 | 48.8 | |||
| III | 19.9 | 18.6 | 16.3 | 17.5 | 15.3 | 15.4 | 18.3 | 14.6 | 12.4 | |||
| Missing | 0.7 | 0.7 | 0 | 0.9 | 0 | 0.6 | 1.4 | 0 | 0.6 | |||
| Histology, % | 0.043 | 0.591 | 0.787 | |||||||||
| IDC | 79.8 | 85.7 | 85.1 | 84.3 | 83.1 | 84.3 | 83.9 | 84.4 | 83.2 | |||
| ILC | 1.9 | 2.7 | 3.9 | 1.5 | 3.7 | 3.7 | 1.9 | 3.4 | 3.2 | |||
| DCIS | 9.7 | 4.9 | 5 | 7.3 | 6.2 | 5.3 | 7.1 | 5.6 | 5.6 | |||
| Others | 8.6 | 6.7 | 6 | 6.9 | 7.1 | 6.7 | 7.1 | 6.6 | 7.9 | |||
| ER status, % | 0.267 | 0.993 | 0.662 | |||||||||
| Positive | 73.1 | 73.1 | 73.4 | 72.8 | 72.8 | 72.5 | 75.1 | 71.2 | 73.8 | |||
| Negative | 23.2 | 23.5 | 25.2 | 24.2 | 24.2 | 25 | 21.3 | 25.6 | 23.5 | |||
| Missing | 3.7 | 3.4 | 1.4 | 3 | 3 | 2.5 | 3.6 | 3.2 | 2.6 | |||
| PR status, % | 0.05 | 0.838 | 0.924 | |||||||||
| Positive | 59.2 | 55.8 | 54.8 | 55.3 | 57.5 | 42.4 | 56 | 55.6 | 55.9 | |||
| Negative | 37.1 | 39.9 | 43.8 | 41.1 | 39.3 | 55.1 | 39.9 | 41.2 | 41.2 | |||
| Missing | 3.7 | 4.3 | 1.4 | 3.6 | 3.2 | 2.5 | 4.1 | 3.2 | 2.9 | |||
| HER 2 status, % | <0.001 | 0.599 | 0.081 | |||||||||
| Positive | 21 | 28.5 | 26.8 | 29 | 27.2 | 24.4 | 24.9 | 27.8 | 23.8 | |||
| Negative | 66.3 | 66.9 | 68.1 | 63.7 | 66.4 | 69.7 | 65.6 | 67.3 | 70 | |||
| Missing | 12.7 | 4.6 | 5 | 7.3 | 6.4 | 5.9 | 9.6 | 4.9 | 6.2 | |||
| Type of surgery | 0.403 | 0.904 | 0.517 | |||||||||
| Mastectomy | 65.9 | 61.6 | 61.2 | 62.2 | 61 | 60.7 | 62 | 61 | 57.9 | |||
| Conservation | 34.1 | 38.4 | 38.8 | 37.8 | 39 | 39.3 | 38 | 39 | 42.1 | |||
| Chemotherapy, % | 0.027 | 0.826 | 0.601 | |||||||||
| Yes | 70 | 78.2 | 77.5 | 75.5 | 76.5 | 77.5 | 72.4 | 75.4 | 75 | |||
| No | 30 | 21.8 | 22.5 | 24.5 | 23.5 | 22.5 | 24.6 | 24.6 | 25 | |||
| Radiotherapy, % | 0.181 | 0.47 | 0.815 | |||||||||
| Yes | 67.4 | 73.4 | 70.2 | 69.2 | 72.8 | 71.3 | 69.9 | 69 | 71.2 | |||
| No | 32.6 | 26.6 | 29.8 | 30.8 | 27.2 | 28.7 | 30.1 | 31 | 28.8 | |||
| Endocrine therapy, % | 0.227 | 0.018 | 0.788 | |||||||||
| Yes | 76.4 | 72.2 | 76.4 | 71 | 78.8 | 71.3 | 75.4 | 74.9 | 73.2 | |||
| No | 23.6 | 27.8 | 23.6 | 29 | 21.1 | 28.7 | 24.6 | 25.1 | 26.8 | |||
| BMI at FU, kg/m2 | 0.001 | 0.153 | 0.001 | |||||||||
| Underweight (<18.5) | 5.2 | 6.3 | 3.9 | 3.6 | 4.8 | 4.5 | 3 | 6.3 | 3.8 | |||
| Normal (18.5–22.9) | 41.9 | 42.3 | 53 | 41.1 | 40.9 | 46.3 | 37.4 | 38.8 | 41.8 | |||
| Overweight (23–24.9) | 19.9 | 20.5 | 22 | 19.3 | 22.4 | 23.3 | 16.9 | 23.9 | 25 | |||
| Obese (≥25) | 33 | 30.9 | 21.1 | 36 | 32 | 25.8 | 42.6 | 31 | 29.4 | |||
| Presence of menopausal symptoms, % | 0.677 | 0.017 | 0.313 | |||||||||
| Yes | 64 | 65.7 | 63.1 | 60.7 | 70.1 | 63.2 | 62.8 | 66.6 | 61.5 | |||
| No | 36 | 34.3 | 36.9 | 39.3 | 29.9 | 36.8 | 37.2 | 33.4 | 38.5 | |||
Abbreviations: FU, follow-up; SD, standard deviation; HKD, Hong Kong dollars; AJCC, American Joint Committee on Cancer; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; DCIS, ductal carcinoma in situ; ER, estrogen receptor; PR, progesterone receptor; HER 2, human epidermal-growth-factor receptor 2; BMI, body mass index; MET, metabolic equivalent of task.
Univariate and multivariate linear regression analyses to investigate the associations of the level of sports activities and QoL scores at 18-month follow-up cross-sectionally (n = 1289).
| EORTC QLQ-C30 | Crude | Adjusted | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Low-Level Group | High-Level Group | Low-Level Group | High-Level Group | |||||||
| Mean Difference | 95% CI | Mean Difference | 95% CI | Mean Difference | 95% CI | Mean Difference | 95% CI | |||
| Global Health status/QoL | 1.43 | 1.08 to 3.95 | 5.44 | 2.79 to 8.09 | <0.001 | 1.32 | 1.06 to 3.69 | 5.07 | 2.56 to 7.57 | <0.001 |
| Functioning | ||||||||||
| Physical Functioning | −0.31 | −1.98 to 1.37 | 2.21 | 0.46 to 3.97 | 0.004 | −0.38 | −1.93 to 1.16 | 1.86 | 0.23 to 3.50 | 0.008 |
| Role Functioning | −0.32 | −2.43 to 1.78 | 1.71 | −0.50 to 3.93 | 0.076 | −0.05 | −2.11 to 2.00 | 2.02 | −0.15 to 4.19 | 0.037 |
| Emotional Functioning | 2.41 | −0.27 to 5.10 | 3.22 | 0.39 to 6.05 | 0.033 | 2.97 | 0.57 to 5.38 | 3.48 | 0.94 to 6.02 | 0.013 |
| Cognitive Functioning | 0.18 | −2.56 to 2.92 | 1.06 | −1.82 to 3.94 | 0.432 | 0.14 | −2.48 to 2.75 | 0.81 | −1.96 to 3.57 | 0.531 |
| Social Functioning | 0.41 | −1.79 to 2.61 | 0.44 | −1.87 to 2.76 | 0.730 | 0.70 | −1.45 to 2.86 | 0.40 | −1.87 to 2.68 | 0.805 |
| Symptoms | ||||||||||
| Fatigue | −0.56 | −3.14 to 2.30 | −4.79 | −7.80 to −1.79 | <0.001 | −0.90 | −3.53 to 1.73 | −4.31 | −7.09 to −1.54 | <0.001 |
| Nausea and vomiting | −0.15 | −1.07 to 0.78 | −0.54 | −1.52 to 0.43 | 0.242 | −0.10 | −1.03 to 0.84 | −0.30 | −1.28 to 0.69 | 0.530 |
| Pain | 1.19 | −2.12 to 4.50 | −3.59 | −7.07 to −0.11 | 0.015 | 1.58 | −1.44 to 4.61 | −2.36 | −5.56 to 0.83 | 0.060 |
| Dyspnea | −0.60 | −3.05 to 1.85 | −3.41 | −5.99 to −0.83 | 0.005 | −0.88 | −3.28 to 1.52 | −2.98 | −5.51 to −0.48 | 0.014 |
| Insomnia | 3.41 | −0.71 to 7.52 | 0.79 | −3.54 to 5.13 | 0.958 | 3.05 | −0.84 to 6.94 | 0.57 | −3.55 to 4.68 | 0.962 |
| Loss of appetite | −0.83 | −2.76 to 1.10 | −2.05 | −4.08 to −0.02 | 0.040 | −0.46 | −2.39 to 1.47 | −1.42 | −3.47 to 0.62 | 0.148 |
| Constipation | −1.94 | −4.81 to 0.92 | −2.58 | −5.59 to 0.44 | 0.109 | −1.82 | −4.72 to 1.09 | −2.54 | −5.61 to 0.54 | 0.119 |
| Diarrhea | 1.57 | −0.22 to 3.35 | −0.51 | −2.39 to 1.37 | 0.329 | 1.15 | −0.64 to 2.94 | −0.66 | −2.56 to 1.23 | 0.286 |
| Financial impact | 0.35 | −3.05 to 3.75 | 0.14 | −3.44 to 3.71 | 0.968 | 1.28 | −2.01 to 4.57 | 1.67 | −1.81 to 5.15 | 0.372 |
Univariate and multivariate linear regression models were used to investigate the associations between the level of sports activities and QoL scores. The adjusted variables included age at follow-up, education level, household income, menopausal status at follow-up, total number of comorbidities, AJCC stage, histology, HER 2 status, chemotherapy, endocrine therapy, BMI at follow-up, and presence of menopausal symptoms at follow-up. Patients in the no sports activity group were treated as the reference in calculating the mean difference of QoL. Abbreviations: 95% CI, 95% confidence intervals; EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30; QoL, quality of life; AJCC, American Joint Committee on Cancer; HER 2, human epidermal-growth-factor receptor 2; BMI, body mass index.
Univariate and multivariate linear regression analyses to investigate the associations of the level of sports activities and QoL scores at 36-month follow-up cross-sectionally (n = 1125).
| EORTC QLQ-C30 | Crude | Adjusted | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Low-Level Group | High-Level Group | Low-level Group | High-Level Group | |||||||
| Mean Difference | 95% CI | Mean Difference | 95% CI | Mean Difference | 95% CI | Mean Difference | 95% CI | |||
| Global Health status/QoL | −0.59 | −3.20 to 2.02 | 3.17 | 0.43 to 5.91 | 0.021 | −0.05 | −2.50 to 2.40 | 2.85 | 0.27 to 5.43 | 0.028 |
| Functioning | ||||||||||
| Physical Functioning | −0.61 | −2.40 to 1.18 | 3.05 | 1.17 to 4.93 | 0.001 | −0.39 | −2.08 to 1.30 | 2.67 | 0.90 to 4.45 | 0.003 |
| Role Functioning | −0.32 | −2.52 to 1.87 | 2.08 | −0.23 to 4.38 | 0.072 | 0.28 | −1.88 to 2.44 | 1.97 | −0.31 to 4.24 | 0.087 |
| Emotional Functioning | −0.16 | −2.78 to 2.47 | 3.11 | 0.36 to 5.86 | 0.002 | 1.60 | −0.75 to 3.95 | 3.46 | 0.99 to 5.93 | 0.006 |
| Cognitive Functioning | −0.43 | −3.22 to 2.36 | 0.76 | −2.16 to 3.69 | 0.598 | 0.69 | −1.88 to 3.26 | 0.46 | −2.25 to 3.17 | 0.748 |
| Social Functioning | −0.65 | −2.71 to 1.42 | 1.68 | −0.49 to 3.84 | 0.119 | −0.23 | −2.28 to 1.82 | 1.37 | −0.79 to 3.52 | 0.205 |
| Symptoms | ||||||||||
| Fatigue | 0.05 | −2.94 to 3.04 | −5.19 | −8.32 to −2.05 | 0.001 | −1.24 | −3.91 to 1.44 | −5.05 | −7.86 to −2.23 | <0.001 |
| Nausea and vomiting | 0.52 | −0.86 to 1.89 | −0.38 | −1.82 to 1.06 | 0.587 | 0.42 | −0.96 to 1.80 | −0.24 | −1.70 to 1.21 | 0.726 |
| Pain | 1.08 | −2.04 to 4.20 | −3.48 | −6.75 to −0.21 | 0.033 | 0.66 | −2.26 to 3.57 | −2.86 | −5.93 to 0.22 | 0.063 |
| Dyspnea | 0.83 | −1.92 to 3.57 | −0.46 | −3.34 to 2.42 | 0.739 | 0.43 | −2.21 to 3.07 | 0.22 | −2.56 to 3.00 | 0.881 |
| Insomnia | 0.99 | −3.20 to 5.18 | −2.05 | −6.44 to 2.34 | 0.347 | −0.85 | −4.77 to 3.07 | −2.60 | −6.73 to 1.53 | 0.214 |
| Loss of appetite | 0.23 | −1.94 to 2.39 | −1.86 | −4.14 to 0.41 | 0.102 | −0.09 | −2.26 to 2.07 | −1.83 | −4.11 to 0.44 | 0.109 |
| Constipation | −3.06 | −6.15 to 0.04 | −5.25 | −8.49 to −2.00 | 0.002 | −3.75 | −6.83 to −0.68 | −5.13 | −8.34 to −1.88 | 0.002 |
| Diarrhea | 0.23 | −1.91 to 2.37 | −1.02 | −3.26 to 1.22 | 0.362 | −0.19 | −2.33 to 1.94 | −1.15 | −3.41 to 1.10 | 0.309 |
| Financial impact | 2.12 | −0.77 to 5.00 | 0.55 | −2.47 to 3.57 | 0.746 | 2.34 | −0.44 to 5.12 | 1.43 | −1.50 to 4.37 | 0.356 |
Univariate and multivariate linear regression models were used to investigate the associations between the level of sports activities and QoL scores. The adjusted variables included age at follow-up, education level, household income, menopausal status at follow-up, total number of comorbidities, AJCC stage, histology, HER 2 status, chemotherapy, endocrine therapy, BMI at follow-up, and presence of menopausal symptoms at follow-up. Patients in the no sports activity group were treated as the reference in calculating the mean difference of QoL. Abbreviations: 95% CI, 95% confidence intervals; EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30; QoL, quality of life; AJCC, American Joint Committee on Cancer; HER 2, human epidermal-growth-factor receptor 2; BMI, body mass index.
Univariate and multivariate linear regression analyses to investigate the associations of the level of sports activities and QoL scores at 60-month follow-up cross-sectionally (n = 1116).
| EORTC QLQ-C30 | Crude | Adjusted | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Low-Level Group | High-Level Group | Low-Level Group | High-Level Group | |||||||
| Mean Difference | 95% CI | Mean Difference | 95% CI | Mean Difference | 95% CI | Mean Difference | 95% CI | |||
| Global Health status/QoL | 1.13 | −1.35 to 3.61 | 6.20 | 3.60 to 8.80 | <0.001 | 1.43 | −0.92 to 3.78 | 5.74 | 3.26 to 8.21 | <0.001 |
| Functioning | ||||||||||
| Physical Functioning | −0.13 | −1.90 to 1.63 | 2.58 | 0.73 to 4.43 | 0.007 | −0.22 | −1.87 to 1.43 | 2.07 | 0.33 to 3.81 | 0.020 |
| Role Functioning | 0.49 | −1.65 to 2.64 | 0.60 | −1.65 to 2.85 | 0.597 | 0.97 | −1.18 to 3.12 | 0.44 | −1.82 to 2.71 | 0.697 |
| Emotional Functioning | 0.06 | −2.45 to 2.56 | 1.92 | 0.71 to 4.54 | 0.157 | 0.62 | −1.66 to 2.91 | 1.40 | −1.01 to 3.80 | 0.253 |
| Cognitive Functioning | −0.34 | −3.08 to 2.40 | 0.66 | −2.21 to 3.53 | 0.661 | −0.04 | −2.61 to 2.52 | −0.05 | −2.75 to 2.65 | 0.971 |
| Social Functioning | −0.53 | −2.43 to 1.36 | −0.18 | −2.16 to 1.81 | 0.852 | −0.53 | −2.39 to 1.34 | −0.95 | −2.92 to 1.02 | 0.342 |
| Symptoms | ||||||||||
| Fatigue | 0.55 | −2.25 to 3.34 | −1.79 | −4.72 to 1.13 | 0.240 | −0.03 | −2.56 to 2.50 | −0.95 | −3.62 to 1.71 | 0.483 |
| Nausea and vomiting | 0.27 | −0.90 to 1.43 | −0.26 | −1.48 to 0.96 | 0.692 | 0.37 | −0.81 to 1.55 | 0.09 | −1.15 to 1.33 | 0.886 |
| Pain | 1.06 | −2.08 to 4.21 | −0.98 | −4.27 to 2.32 | 0.577 | 1.22 | −1.69 to 4.14 | 0.09 | −2.98 to 3.17 | 0.949 |
| Dyspnea | −0.26 | −2.79 to 2.27 | −1.14 | −3.79 to 1.51 | 0.402 | −0.13 | −2.59 to 2.33 | 0.10 | −2.49 to 2.70 | 0.938 |
| Insomnia | 4.56 | 0.45 to 8.67 | 3.69 | −0.61 to 8.00 | 0.086 | 4.07 | 0.20 to 7.94 | 4.40 | 0.32 to 8.48 | 0.034 |
| Loss of appetite | 0.42 | −1.49 to 2.34 | −2.19 | −4.20 to −0.19 | 0.036 | 0.43 | −1.47 to 2.33 | −1.62 | −3.62 to 0.38 | 0.115 |
| Constipation | −0.93 | −4.07 to 2.22 | −3.54 | −6.84 to −0.25 | 0.036 | −1.63 | −4.79 to 1.53 | −3.32 | −6.64 to 0.01 | 0.050 |
| Diarrhea | 0.22 | −1.88 to 2.32 | −1.38 | −3.58 to 0.81 | 0.225 | 0.23 | −1.88 to 2.34 | −0.85 | −3.08 to 1.37 | 0.455 |
| Financial impact | −0.31 | −2.99 to 2.37 | −1.38 | −4.19 to 1.43 | 0.340 | 0.14 | −2.48 to 2.75 | 0.01 | −2.75 to 2.76 | 0.997 |
Univariate and multivariate linear regression models were used to investigate the associations between the level of sports activities and QoL scores. The adjusted variables included age at follow-up, education level, household income, menopausal status at follow-up, total number of comorbidities, AJCC stage, histology, HER 2 status, chemotherapy, endocrine therapy, BMI at follow-up, and presence of menopausal symptoms at follow-up. Patients in the no sports activity group were treated as the reference in calculating the mean difference of QoL. Abbreviations: 95% CI, 95% confidence intervals; EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30; QoL, quality of life; AJCC, American Joint Committee on Cancer; HER 2, human epidermal-growth-factor receptor 2; BMI, body mass index.
Univariate and multivariate linear regression analyses to investigate the associations of the level of sports activities and QoL scores at 60-month follow-up cross-sectionally (n = 1116).
| EORTC QLQ-C30 | Model 1 | Model 2 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Low-Level Group | High-Level Group | Low-Level Group | High-Level Group | |||||||
| Mean Difference | 95% CI | Mean Difference | 95% CI | Mean Difference | 95% CI | Mean Difference | 95% CI | |||
| Global Health status/QoL | 0.67 | −1.0 to 2.34 | 4.9 | 3.03 to 6.80 | <0.001 | 0.97 | −0.51 to 2.45 | 4.53 | 2.85 to 6.20 | <0.001 |
| Functioning | ||||||||||
| Physical Functioning | −0.33 | −1.52 to 0.86 | 2.61 | 1.38 to 3.83 | <0.001 | −0.27 | −1.35 to 0.80 | 2.25 | 1.16 to 3.34 | <0.001 |
| Role Functioning | −0.09 | −1.50 to 1.32 | 1.49 | −0.01 to 3.00 | 0.042 | 0.29 | −1.09 to 1.66 | 1.53 | 0.09 to 2.97 | 0.030 |
| Emotional Functioning | 0.78 | −0.98 to 2.53 | 1.92 | 0.68 to 4.62 | 0.007 | 1.77 | 0.27 to 3.28 | 2.75 | 1.10 to 4.40 | 0.001 |
| Cognitive Functioning | −0.20 | −2.06 to 1.66 | 0.88 | −1.27 to 2.88 | 0.419 | 0.26 | −1.42 to 1.94 | 0.54 | −1.31 to 2.38 | 0.567 |
| Social Functioning | −0.24 | −1.52 to 1.04 | 0.60 | −0.85 to 2.05 | 0.389 | −0.02 | −1.23 to 1.19 | 0.30 | −1.05 to 1.66 | 0.644 |
| Symptoms | ||||||||||
| Fatigue | 0.08 | −1.90 to 2.07 | −3.90 | −6.03 to −1.77 | <0.001 | −0.73 | −2.42 to 0.97 | −3.52 | −5.28 to −1.75 | <0.001 |
| Nausea and vomiting | 0.21 | −0.49 to 0.91 | −0.37 | −1.08 to 0.33 | 0.261 | 0.22 | −0.48 to 0.92 | −0.14 | −0.82 to 0.54 | 0.631 |
| Pain | 1.19 | −0.89 to 3.28 | −2.71 | −4.94 to −0.48 | 0.011 | 1.17 | −0.66 to 3.00 | −1.74 | −3.67 to 0.19 | 0.011 |
| Dyspnea | 0.08 | −1.57 to 1.73 | −1.68 | −3.43 to 0.07 | 0.049 | −0.05 | −1.59 to 1.50 | −0.91 | −2.55 to 0.73 | 0.051 |
| Insomnia | 3.05 | 0.37 to 5.72 | 0.82 | −2.16 to 3.80 | 0.682 | 2.06 | −0.32 to 4.44 | 0.64 | −1.99 to 3.27 | 0.713 |
| Loss of appetite | −0.08 | −1.37 to 1.20 | −1.98 | −3.22 to −0.75 | 0.001 | −0.13 | −1.38 to 1.12 | −1.62 | −2.83 to −0.40 | 0.006 |
| Constipation | −2.04 | −4.14 to 0.06 | −3.74 | −6.02 to −1.47 | 0.001 | −2.45 | −4.49 to −0.42 | −3.64 | −5.83 to −1.44 | 0.001 |
| Diarrhea | 0.66 | −0.57 to 1.90 | −1.02 | −2.26 to 0.21 | 0.078 | 0.44 | −0.77 to 1.64 | −0.98 | −2.19 to 0.22 | 0.082 |
| Financial impact | 0.67 | −1.28 to 2.62 | −0.22 | −2.33 to 1.90 | 0.798 | 1.17 | −0.67 to 3.02 | 1.09 | −0.88 to 3.06 | 0.302 |
Generalized estimating equations were used to investigate the associations between the level of physical activity and QoL scores. Model 1, adjusted for follow-up time-points; Model 2, further adjusted for age at follow-up, education level, household income, menopausal status at follow-up, total number of comorbidities, AJCC stage, histology, HER 2 status, chemotherapy, endocrine therapy, BMI at follow-up, and presence of menopausal symptoms at follow-up. Patients in the no sports activity group were treated as the reference in calculating the mean difference of QoL. Abbreviations: 95% CI, 95% confidence intervals; EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30; QoL, quality of life; AJCC, American Joint Committee on Cancer; HER 2, human epidermal-growth-factor receptor 2; BMI, body mass index.